Crizotinib
Crizotinib is a newly initially approved drug by the FDA. Crizotinib is an oral tyrosine kinase inhibitor which is used for the treatment of patient with locally advanced or metastatic non small cell lung cancer that has to be positive as an anaplastic lymphoma kinase (ALK) which is a FDA approved test. The treatment with crizotinib is response rate based. Crizotinib has demonstratedconcentration dependent inhibition of ALK & c-met phosphorylation in cell based assay using tumor cell line and demonstrated antitumor activity.
Primary Characteristics
It belongs to Tyrosine kinase inhibitor pharmacological group on the basis of mechanism of action.
Molecular Weight: 450.34 · pKa: 9.4 · Non-proprietary name: Crizotinib.
Pharmacokinetics
Absorption: Crizotinib has an oral bioavailability is 21.5% (±21.5%).
Distribution: Crizotinib has a volume of distribution is 1772 L.. plasma protein binding is 91%.
Elimination: plasma half-life is 42hr, renal excretion is 63% in feces and 22%in urine.
Advertisement
Indications
Crizotinib is primarily indicated in conditions like Non small cell lung cancer.
Contraindications
None recorded.
Dosage
Crizotinib's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 250 mg | 250 mg | Every 2h | p/o | as long as the path is deriving benefit from theeapy. |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Crizotinib is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Diarrhea, Nausea, Yision disorder, Yomiting.
Warnings / Precautions
Available Brands
None recorded.